Sensitivity of immunofluorescence studies vs enzyme-linked immunosorbent assay for diagnosis of bullous pemphigoid

Archives of Dermatology

Volumn 147, Issue 12, 2011, Pages 1454-1456

  Di Zenzo, Giovanni ^a   Joly, Pascal ^b   Zambruno, Giovanna ^a   Borradori, Luca ^c  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ANTIGEN DETECTION; BULLOUS PEMPHIGOID; CLINICAL FEATURE; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; NOTE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SALT SPLIT SKIN; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE SECTION;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; PEMPHIGOID, BULLOUS;

EID: 84255167406     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.147.12.1454-b     Document Type: Note

References (19)

1. Chan LS. ELISA instead of indirect IF in patients with BP. Arch Dermatol. 2011;147(3):291-292.
2. Joly P, Courville P, Lok C, et al French Bullous Study Group. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology. 2004;208(1):16-20. (Pubitemid 38142328)
3. Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004;151(1):112-118. (Pubitemid 39061287)
4. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol. 2011;147(3):286-291.
5. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109(5):679-683. (Pubitemid 27465925)
6. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol. 1998;139(3):365-370. (Pubitemid 28430449)
7. Hata Y, Fujii Y, Tsunoda K, Amagai M. Production of the entire extracellu-lar domain of BP180 (type XVII collagen) by baculovirus expression. J Dermatol Sci. 2000;23(3):183-190. (Pubitemid 30665768)
8. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002;30(3):224-232. (Pubitemid 35351315)
9. Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002; 119(5):1065-1073. (Pubitemid 35430484)
10. Sakuma-Oyama Y, Powell AM, Oyama N, Albert S, Bhogal BS, Black MM. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol. 2004;151(1):126-131. (Pubitemid 39061289)
11. Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol. 2004;151(5):1004-1010. (Pubitemid 39573888)
12. Tsuji-Abe Y, AkiyamaM, Yamanaka Y, Kikuchi T, Sato-Matsumura KC, Shimizu H. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci. 2005;37(3):145-149. (Pubitemid 40331924)
13. Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci. 2006;41(1):21-30. (Pubitemid 43075429)
14. Sitaru C, Dähnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol. 2007;16(9):770-777. (Pubitemid 47261869)
15. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008;128(3):415-426.
16. Feng S, Wu Q, Jin P, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Int JDermatol. 2008;47(3):225-228. (Pubitemid 351266838)
17. Tampoia M, Lattanzi V, Zucano A, et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid.AnnNYAcad Sci. 2009;1173:15-20.
18. Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol. 2011;147(3):293-298.
19. Bernard P, Reguiai Z, Tancrède-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol. 2009;145(5):537-542.